• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

马耳他的 COVID-19 疫情第一波;全国性横断面研究。

The first wave of COVID-19 in Malta; a national cross-sectional study.

机构信息

Department of Medicine, Mater Dei Hospital, Msida, Malta.

Department of Infectious Diseases, Mater Dei Hospital, Msida, Malta.

出版信息

PLoS One. 2020 Oct 15;15(10):e0239389. doi: 10.1371/journal.pone.0239389. eCollection 2020.

DOI:10.1371/journal.pone.0239389
PMID:33057434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7561161/
Abstract

INTRODUCTION

The COVID-19 pandemic has posed major challenges to all aspects of healthcare. Malta's population density, large proportion of elderly and high prevalence of diabetes and obesity put the country at risk of uncontrolled viral transmission and high mortality. Despite this, Malta achieved low mortality rates compared to figures overseas. The aim of this paper is to identify key factors that contributed to these favorable outcomes.

METHODS

This is a retrospective, observational, nationwide study which evaluates outcomes of patients during the first wave of the pandemic in Malta, from the 7th of March to the 24th of April 2020. Data was collected on demographics and mode of transmission. Hospitalization rates to Malta's main general hospital, Mater Dei Hospital, length of in-hospital stay, intensive care unit admissions and 30-day mortality were also analyzed.

RESULTS

There were 447 confirmed cases in total; 19.5% imported, 74.2% related to community transmission and 6.3% nosocomially transmitted. Ninety-three patients (20.8%) were hospitalized, of which 4 were children. Patients with moderate-severe disease received hydroxychloroquine and azithromycin, in line with evidence available at the time. A total of 4 deaths were recorded, resulting in an all-cause mortality of 0.89%. Importantly, all admitted patients with moderate-severe disease survived to 30-day follow up.

CONCLUSION

Effective public health interventions, widespread testing, remote surveillance of patients in the community and a low threshold for admission are likely to have contributed to these favorable outcomes. Hospital infection control measures were key in preventing significant nosocomial spread. These concepts can potentially be applied to stem future outbreaks of viral diseases. Patients with moderate-severe disease had excellent outcomes with no deaths reported at 30-day follow up.

摘要

简介

COVID-19 大流行给医疗保健的各个方面都带来了重大挑战。马耳他的人口密度大、老年人口比例高、糖尿病和肥胖症患病率高,这使得该国面临病毒传播失控和高死亡率的风险。尽管如此,与海外数据相比,马耳他的死亡率仍然较低。本文旨在确定促成这些有利结果的关键因素。

方法

这是一项回顾性、观察性的全国性研究,评估了 2020 年 3 月 7 日至 4 月 24 日马耳他第一波大流行期间患者的结果。数据收集了人口统计学和传播途径。还分析了马耳他主要综合医院 Mater Dei 医院的住院率、住院时间、重症监护病房入院和 30 天死亡率。

结果

总共有 447 例确诊病例;19.5%为输入性病例,74.2%与社区传播有关,6.3%为医院内传播。93 例(20.8%)患者住院,其中 4 例为儿童。中度至重度疾病患者接受羟氯喹和阿奇霉素治疗,符合当时的证据。共记录了 4 例死亡,总死亡率为 0.89%。重要的是,所有中度至重度疾病的住院患者均存活至 30 天随访。

结论

有效的公共卫生干预措施、广泛的检测、对社区患者的远程监测以及较低的入院门槛可能促成了这些有利结果。医院感染控制措施是防止严重医院内传播的关键。这些概念可能有助于阻止未来病毒性疾病的爆发。中度至重度疾病患者的预后良好,30 天随访时无死亡报告。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c23/7561161/20e1f0193009/pone.0239389.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c23/7561161/6e258058589f/pone.0239389.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c23/7561161/f05eab274734/pone.0239389.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c23/7561161/4ea7096f8431/pone.0239389.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c23/7561161/20e1f0193009/pone.0239389.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c23/7561161/6e258058589f/pone.0239389.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c23/7561161/f05eab274734/pone.0239389.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c23/7561161/4ea7096f8431/pone.0239389.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c23/7561161/20e1f0193009/pone.0239389.g004.jpg

相似文献

1
The first wave of COVID-19 in Malta; a national cross-sectional study.马耳他的 COVID-19 疫情第一波;全国性横断面研究。
PLoS One. 2020 Oct 15;15(10):e0239389. doi: 10.1371/journal.pone.0239389. eCollection 2020.
2
Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.阿奇霉素联合羟氯喹治疗因 2019 冠状病毒病(COVID-19)入住重症监护病房的患者:随机对照试验 AZIQUINE-ICU 的方案。
Trials. 2020 Jul 8;21(1):631. doi: 10.1186/s13063-020-04566-x.
3
Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.COVID-19 住院患者中阿奇霉素和羟氯喹的主动预防(ProPAC-COVID):统计分析计划。
Trials. 2020 Oct 20;21(1):867. doi: 10.1186/s13063-020-04795-0.
4
Malta's only acute public hospital service during COVID-19: a diary of events from the first wave to transition phase.马耳他在 COVID-19 期间唯一的急性公立医院服务:第一波到过渡阶段的事件日记。
Int J Qual Health Care. 2021 Feb 20;33(1). doi: 10.1093/intqhc/mzaa138.
5
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.意大利伦巴第地区 1591 名 ICU 收治的 SARS-CoV-2 感染患者的基线特征和结局。
JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394.
6
Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March-April 2020.2020 年 3 月至 4 月,美国北加州非紧急状况下的冠状病毒疾病患者的特征和结局。
Emerg Infect Dis. 2020 Aug;26(8):1679-1685. doi: 10.3201/eid2608.201776. Epub 2020 May 14.
7
A Retrospective Analysis and Comparison of Prisoners and Community-Based Patients with COVID-19 Requiring Intensive Care During the First Phase of the Pandemic in West Texas.西德克萨斯州大流行第一阶段需要重症监护的新冠肺炎囚犯与社区患者的回顾性分析与比较
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720954687. doi: 10.1177/2150132720954687.
8
Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.托珠单抗治疗 80 天后严重 COVID-19 肺炎的经验:一项回顾性队列研究。
J Autoimmun. 2020 Nov;114:102523. doi: 10.1016/j.jaut.2020.102523. Epub 2020 Jul 16.
9
COVID-19, Australia: Epidemiology Report 16 (Reporting week to 23:59 AEST 17 May 2020).2019冠状病毒病,澳大利亚:流行病学报告16(截至澳大利亚东部标准时间2020年5月17日23:59的报告周)
Commun Dis Intell (2018). 2020 May 22;44. doi: 10.33321/cdi.2020.44.45.
10
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.一项干扰素 β-1a 治疗重症 COVID-19 的疗效和安全性的随机临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01061-20.

引用本文的文献

1
The Impact of the COVID-19 Pandemic on Injury Patterns in Inpatient and Outpatient Orthopaedic Trauma.2019年冠状病毒病大流行对骨科创伤住院和门诊患者损伤模式的影响。
Surg J (N Y). 2022 Dec 26;8(4):e302-e307. doi: 10.1055/s-0042-1757427. eCollection 2022 Oct.
2
The Italian policy of mandating SARS-CoV-2 vaccination for healthcare workers: Analysis of the policy processes and preliminary outcomes.意大利对医护人员强制接种 SARS-CoV-2 疫苗的政策:政策过程分析及初步结果。
Health Policy. 2023 Feb;128:49-54. doi: 10.1016/j.healthpol.2022.11.006. Epub 2022 Nov 18.
3
COVID-19 in Malaysia: Descriptive Epidemiologic Characteristics of the First Wave.

本文引用的文献

1
COVID-19 panic, solidarity and equity-the Malta exemplary experience.新冠疫情引发的恐慌、团结与公平——马耳他的典型经验
Z Gesundh Wiss. 2022;30(2):459-464. doi: 10.1007/s10389-020-01308-w. Epub 2020 May 30.
2
Lessons in contact tracing from Germany.德国接触者追踪的经验教训。
BMJ. 2020 Jun 25;369:m2522. doi: 10.1136/bmj.m2522.
3
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤回:羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎:一项多国注册分析
马来西亚的 2019 冠状病毒病:第一波疫情的描述性流行病学特征。
Int J Environ Res Public Health. 2022 Mar 23;19(7):3828. doi: 10.3390/ijerph19073828.
4
Managing COVID-19 in four small countries: Initial response to the pandemic in San Marino, Montenegro, Malta and Cyprus.管理 COVID-19 在四个小国:圣马力诺、黑山、马耳他和塞浦路斯对大流行的初步反应。
Health Policy. 2022 Apr;126(4):281-286. doi: 10.1016/j.healthpol.2022.01.008. Epub 2022 Jan 21.
5
Reproducibility of Research During COVID-19: Examining the Case of Population Density and the Basic Reproductive Rate from the Perspective of Spatial Analysis.COVID-19 期间研究的可重复性:从空间分析角度审视人口密度与基本繁殖数的案例
Geogr Anal. 2021 Nov 18. doi: 10.1111/gean.12307.
6
Digital SARS-CoV-2 Detection Among Hospital Employees: Participatory Surveillance Study.医疗机构员工中新型冠状病毒数字检测:参与性监测研究。
JMIR Public Health Surveill. 2021 Nov 22;7(11):e33576. doi: 10.2196/33576.
7
Insight into the Occurrence of Common Non-communicable Diseases at a Population Level and the Potential Impact During the Coronavirus Pandemic - a Need for a Syndemic Healthcare Approach?洞察人群层面常见非传染性疾病的发生情况以及新冠疫情期间的潜在影响——是否需要一种共病医疗方法?
SN Compr Clin Med. 2021;3(12):2393-2400. doi: 10.1007/s42399-021-01064-2. Epub 2021 Sep 22.
8
Healthcare-associated COVID-19 in England: A national data linkage study.英格兰与医疗保健相关的 COVID-19:一项全国性的数据关联研究。
J Infect. 2021 Nov;83(5):565-572. doi: 10.1016/j.jinf.2021.08.039. Epub 2021 Aug 30.
9
Correction: The first wave of COVID-19 in Malta; a national cross-sectional study.更正:马耳他的第一波新冠疫情;一项全国性横断面研究。
PLoS One. 2021 Aug 3;16(8):e0255881. doi: 10.1371/journal.pone.0255881. eCollection 2021.
10
Evaluation of COVID-19 Disease and the Effect of Trends in Intervention Measures: The Pediatric Perspective from a Tertiary Care Hospital in Turkey.评估 COVID-19 疾病及干预措施趋势的影响:土耳其一家三级保健医院的儿科视角。
Balkan Med J. 2021 Jul;38(4):222-228. doi: 10.5152/balkanmedj.2021.21045.
Lancet. 2020 May 22. doi: 10.1016/S0140-6736(20)31180-6.
4
The UK's public health response to covid-19.英国对新冠疫情的公共卫生应对措施。
BMJ. 2020 May 15;369:m1932. doi: 10.1136/bmj.m1932.
5
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].羟氯喹治疗中度新型冠状病毒肺炎患者的一项试点研究
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
6
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的观察性研究。
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
7
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者,没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
8
National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management.国家传染病研究所“L. 斯帕兰扎尼”,意大利康复中心。新型冠状病毒肺炎临床管理建议。
Infect Dis Rep. 2020 Mar 16;12(1):8543. doi: 10.4081/idr.2020.8543. eCollection 2020 Feb 25.
9
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19:一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
10
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.